Abstracts tagged "Bone density"

Abstract Number: 373 • 2013 ACR/ARHP Annual Meeting
Menopause Occurs Earlier and Is An Independent Risk Factor For Osteoporosis In Women With Rheumatoid Arthritis
Michael Cocker¹, Alexander Oldroyd² and Marwan Bukhari³, ¹Rheumatology, Royal Lancaster Infirmary, Lancaster, United Kingdom, ²Lancaster Medical School, Lancaster University, Lancaster, United Kingdom, ³Department of Rheumatology, Royal Lancaster Infirmary, Lancaster, United Kingdom
Background/Purpose: Rheumatoid arthritis (RA) and early menopause (
Abstract Number: 2262 • 2013 ACR/ARHP Annual Meeting
Antibody To Malondialdehyde-Acetaldehyde Adducts (MAA) Is a Biomarker Of Inflammation and Is Correlated With The Disease Activity In Rheumatoid Arthritis
Kathleen Young¹, Dathe Benissan-Messan², Michael J. Duryee³, Daniel Anderson⁴, Liron Caplan^5,6, Lisa A. Davis^7,8,9, Harlan Sayles⁴, Carlos D. Hunter³, Lynell W. Klassen¹⁰, James R. O'Dell¹¹, Ted R. Mikuls⁴ and Geoffrey M Thiele¹², ¹Int Med/Sec of Rheum/Immun, University of Nebraska Medical Center, Omaha, NE, ²Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ³Internal Medicine Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁴Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁵Department of Medicine, Denver Veterans Affairs Medical Center, Denver, CO, ⁶Department of Medicine, University of Colorado School of Medicine, Aurora, CO, ⁷Division of Rheumatology, Univ. of Colorado Sch. of Medicine, Aurora, CO, ⁸Division of Rheumatology, Denver Health and Hospital Authority, Denver, CO, ⁹Denver Veterans Affairs Medical Center, Denver, CO, ¹⁰Dept of Internal Medicine, Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ¹¹Dept of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ¹²Internal Medicine, Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Cardiovascular disease (CVD) is a major cause of morbidity and mortality in patients with rheumatoid arthritis (RA). While there are many markers used…
Abstract Number: 1785 • 2013 ACR/ARHP Annual Meeting
Structural Determinants Of Low Vertebral Strength In Pediatric Systemic Lupus Erythematosus
Jon M. Burnham¹, Babette S. Zemel¹, David C. Lee², Tony M. Keaveny³ and Mary Beth Leonard¹, ¹Pediatrics, The Children's Hospital of Philadelphia and the Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²O.N. Diagnostics, LLC, Berkeley, CA, ³Founder and Chief Science Officer, University of California, Berkeley, CA and O.N. Diagnostics, LLC, Berkeley, CA
Background/Purpose: Children with systemic lupus erythematosus (SLE) are at high risk for bone fragility. Studies in pediatric SLE using two-dimensional lumbar spine (LS) dual X-ray…
Abstract Number: 1548 • 2013 ACR/ARHP Annual Meeting
Effect Of TNF Inhibitors On Bone Mineral Density In Patients With Ankylosing Spondylitis- a Systematic Review and Meta-Analysis
Nisha Nigil Haroon¹, Jeevitha Srighanthan², Nayef AL Ghanim³, Robert D. Inman^4,5,6,7,8,9 and Angela Cheung¹⁰, ¹Medicine, University of Toronto, Toronto, ON, Canada, ²Osteoporosis Program, University of Toronto, Ontario, ON, Canada, ³Rheumatology, University of Toronto, Toronto, ON, Canada, ⁴Toronto Western Hospital, Toronto, ON, Canada, ⁵Rheumatology, Toronto Western Research Institute. University of Toronto, Toronto, ON, Canada, ⁶University of Toronto, Toronto, ON, Canada, ⁷Dept of Medicine/Rheumatology, Toronto Western Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, ⁸U of Toronto, Toronto, ON, Canada, ⁹Dept of Medicine/Rheumatology, The Arthritis Program, Toronto Western Hospital and Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ¹⁰Department of Medicine, University of Toronto, Toronto, ON, Canada
Background/Purpose: Patients with ankylosing spondylitis (AS) are susceptible to osteoporosis (OP) and have high fracture risk. Currently, no specific strategies are established to treat OP…
Abstract Number: 1237 • 2013 ACR/ARHP Annual Meeting
Denosumab Leads To Significantly Greater Increases In Bone Mineral Density Than Ibandronate and Risedronate In Postmenopausal Women At High Risk For Fracture Who Were Previously Treated With An Oral Bisphosphonate
Jacques P. Brown¹, Michael A. Bolognese², Pei-Ran Ho³, Jesse Hall³, Christian Roux⁴, Henry G. Bone⁵, Sydney Bonnick⁶, Joop van den Bergh⁷, Irene Ferreira⁸, Prayashi Ghelani⁹, Paula Dakin³, Rachel B. Wagman³ and Chris Recknor¹⁰, ¹CHU de Québec Research Centre and Laval University, Quebec City, QC, Canada, ²Bethesda Health Research Center, Bethesda, MD, ³Amgen Inc., Thousand Oaks, CA, ⁴Paris Descartes University, Paris, France, ⁵Michigan Bone and Mineral Clinic, Detroit, MI, ⁶Clinical Research Center of North Texas, Denton, TX, ⁷VieCuri Medical Centre and Maastricht University, Venlo, Netherlands, ⁸Amgen Inc., Cambridge, United Kingdom, ⁹Ovatech Solutions, London, United Kingdom, ¹⁰United Osteoporosis Centers, Gainesville, GA
Denosumab Leads to Significantly Greater Increases in Bone Mineral Density Than Ibandronate and Risedronate in Postmenopausal Women at High Risk for Fracture Who Were Previously…
Abstract Number: 1239 • 2013 ACR/ARHP Annual Meeting
The Effects Of Hyperparathyroidism On Body Mass Index and Bone Mineral Density- An Observational Case-Control Study
Chris Varley¹, Alexander Oldroyd² and Marwan Bukhari³, ¹Lancaster Medical School, Lancaster University, Llandudno, United Kingdom, ²Lancaster Medical School, Lancaster University, Lancaster, United Kingdom, ³Department of Rheumatology, Royal Lancaster Infirmary, Lancaster, United Kingdom
Background/Purpose: Hyperparathyroidism is associated with reduced bone mineral density (BMD) and increased fracture risk. A previous study from this group has shown that bone loss…
Abstract Number: 1222 • 2013 ACR/ARHP Annual Meeting
Analysis Of Corelation Of Bone Mineral Density Of Spine With Other Sites In Ankylosing Spondylitis As Compared To Rheumatoid Arthritis and Control Populations
Janie Bruce¹ and Vikas Majithia^2,3, ¹Div of Rheumatology, University of Mississippi School of Medicine, Jackson, MS, ²Div of Rheumatology, University of Mississippi Medical Center, Jackson, MS, ³G.V. "Sonny" Montogomery VA Medical Center, Jackson, MS
Background/Purpose: Bone mineral density (BMD) at the 3 central sites usually correlates with each other but the effect of disease states on this correlation is…
Abstract Number: 1230 • 2013 ACR/ARHP Annual Meeting
Analysis Of Fracture Risk Assessment Score (FRAX) Correlation With Bone Mineral Density (BMD) In Males and Post-Menopausal Females
Vikas Majithia¹ and Khush Aujla², ¹Div of Rheumatology, University of Mississippi Medical Center, Jackson, MS, ²Division of Rheumatology, University of Mississippi School of Medicine, Jackson, MS
Background/Purpose: Fracture Risk Assessment Tool (FRAX) is a useful clinical tool for assessment of fracture risk and a major development in evaluation of osteoporosis. Its…
Abstract Number: 1219 • 2013 ACR/ARHP Annual Meeting
Phase 3 Fracture Trial Of Odanacatib For Osteoporosis – Baseline Characteristics and Study Design
Socrates Papapoulos¹, Henry G. Bone², David W. Dempster³, John Eisman⁴, Susan Greenspan⁵, Michael McClung⁶, Toshitaka Nakamura⁷, Joseph Shih⁸, Albert Leung⁹, Arthur Santora¹⁰, N. Verbruggen¹¹ and Antonio Lombardi¹², ¹Leiden University Medical Center, Leiden, Netherlands, ²Michigan Bone and Mineral Clinic, Detroit, MI, ³Regional Bone Center, Helen Hayes Hospital, West Haverstraw, NY, ⁴The Garvan Institute of Medical Research, Sydney, Australia, ⁵University of Pittsburgh, Pittsburgh, PA, ⁶Oregon Osteoporosis Center, Portland, OR, ⁷University of Occupational & Environmental Health, Fukuoaka, Japan, ⁸Robert Wood Johnson Medical School, Piscataway, NJ, ⁹Clinical Research, Merck Sharp and Dohme Corp., Rahway, NJ, ¹⁰Merck Sharp & Dohme Corp., Whitehouse Station, NJ, ¹¹MSD Belgium, Brussels, Belgium, ¹²Merck Sharp and Dohme Corp., Rahway, NJ
Background/Purpose: Odanacatib is a selective and reversible inhibitor of cathepsin K; a collagenase secreted by osteoclasts, and is currently being evaluated for the treatment of…
Abstract Number: 1221 • 2013 ACR/ARHP Annual Meeting
The Effects Of Hyperthyroidism On Bone Mineral Density At Different Sites- An Observational Case-Control Study
Christopher Varley¹, Alexander Oldroyd¹ and Marwan Bukhari², ¹Lancaster Medical School, Lancaster University, Lancaster, United Kingdom, ²Department of Rheumatology, Royal Lancaster Infirmary, Lancaster, United Kingdom
Background/Purpose: Hyperthyroidism has been described as a risk factor for poor bone health.1, 2 The FRAXTM tool has been used to identify the ten year…
Abstract Number: 1225 • 2013 ACR/ARHP Annual Meeting
FRAX 10-Year Fracture Risk In Women With a Fracture Of The Distal Forearm: Agreement Between Assessments With and Without Bone Mineral Density and Influence Of Measurement Side In Individual Patients
Emilie Egsmose¹, Mette Birkvig², Thora Buhl³ and Ole Rintek Madsen³, ¹Copenhagen University Hospital Hvidovre, Copenhagen, Denmark, ²Osteoporosis Clinic, Copenhagen University Hospital Gentofte, Copenhagen, Denmark, ³Copenhagen University Hospital Gentofte, Copenhagen, Denmark
Background/Purpose: The FRAX® tool has been developed by WHO to evaluate fracture (Fx) risk of patients. It is based on individual patient models that integrate…
Abstract Number: 1234 • 2013 ACR/ARHP Annual Meeting
Effects Of Biological Therapy In Bone Metabolism In Patients With Chronic Inflammatory Arthropathies
Maria Victoria Hernández¹, Andrea Cuervo², Pilar Peris¹, Ana Monegal¹, Raimon Sanmarti¹, Juan D. Cañete¹ and Nuria Guañabens¹, ¹Rheumatology, Hospital Clínic of Barcelona. IDIBAPS. University of Barcelona, Barcelona, Spain, ²Arthritis Unit. Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain
Background/Purpose: The efficacy of biological agents in the treatment of chronic inflammatory arthropathies is well known, however, the effect of this therapy in bone metabolism…
Abstract Number: 2583 • 2012 ACR/ARHP Annual Meeting
Bone Structure and Perfusion Quantification of Bone Marrow Edema and Pannus Tissue Areas in the Wrist of Patients with RA
Jose R. Teruel Antolin¹, Andrew J. Burghardt², Julien Rivoire¹, Waraporn Srikhum¹, Susan M. Noworolski³, Thomas M. Link¹, John B. Imboden⁴ and Xiaojuan Li⁵, ¹Musculoskeletal Quantitative Imaging Research Group, Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, ²Department of Radiology & Biomedical Imaging, Musculoskeletal Quantitative Imaging Research, UCSF, San Francisco, CA, ³Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, ⁴Department of Medicine, Division of Rheumatology, UCSF, San Francisco, CA, ⁵Department of Radiology and Biomedical Imaging, Musculoskeletal Quantitative Imaging Research, UCSF, San Francisco, CA
Background/Purpose: Bone marrow edema (BME) has been suggested as a strong predictor for erosive progression in RA joints, however, no previous studies examined the bone…
Abstract Number: 1117 • 2012 ACR/ARHP Annual Meeting
Association Between Hip Bone Marrow Lesions (BMLs) and Bone Mineral Density: A Cross-Sectional and Longitudinal Population-Based Study
Harbeer Ahedi¹, Dawn Dore¹, Leigh Blizzard², Flavia Cicuttini³ and Graeme Jones⁴, ¹Musculoskeletal Unit, Menzies Research institute Tasmania, University of Tasmania, Hobart, 7000, Australia, ²Statistics, Menzies Research Institute Tasmania, University of Tasmania, Hobart, Tasmania, Australia, ³Department of Epidemiology and Preventive Medicine, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, 3004, Australia, ⁴Musculoskeletal Unit, Menzies Research Institute Tasmania, University of Tasmania, Hobart,7000, Australia
Background/Purpose: Bone marrow lesions (BMLs) have been identified one of the key pathologic features in knee osteoarthritis (OA) 1. However, there is limited data on…
Abstract Number: 2408 • 2012 ACR/ARHP Annual Meeting
Effects of Ground and Joint Reaction Force Exercise On Bone Mineral Density in Postmenopausal Women: A Meta-Analysis of Randomized Controlled Trials
George A. Kelley¹, Kristi S. Kelley¹ and Wendy M. Kohrt², ¹Biostatistics, West Virginia University, Morgantown, WV, ²Geriatric Medicine, University of Colorado @ Denver, Aurora, CO
Background/Purpose: Previous randomized controlled trials have led to conflicting findings regarding the effects of ground and/or joint reaction force exercise on femoral neck (FN) and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.